by Jan | Mar 16, 2021 | 2021, News
CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group,...
by Jan | Jan 12, 2021 | 2021, News
A second financing round was closed with NBank Capital, the investment company of NBank. Additional investors came from the private sector in Braunschweig. CORAT Therapeutics is in close coordination with the regulatory authorities and expects the green light for the...
by Jan | Dec 18, 2020 | 2020, News
COR-101 decreased SARS-CoV-2 virus load in the lung by more than 99%COR-101 induced recovery after 2 days, compared to 7 days untreated CORAT Therapeutics GmbH today reports the successful conclusion of hamster disease model tests of their lead candidate COR-101...
by Jan | Dec 4, 2020 | 2020, News
Because SARS-CoV-2 is a novel virus, many people have not yet developed antibodies against the pathogen. Vaccines can protect healthy people, but they cannot cure people affected by COVID-19. Furthermore, not everyone responds to the vaccine. Passive immunisation by...
by Jan | Dec 2, 2020 | 2020, News
Durchstarterpreis award ceremony “And the winner is: CORAT Therapeutics!” The online award ceremony with the Nominees (top) and Stefan Muhle, Dr. Althusmann and Dr. Sabine Johannsen (left to right). (Photos: NBank) In an event with Economics Minister Dr....
by Jan | Nov 15, 2020 | 2020, News
15.11.2020 – CORAT Therapeutics CEO Dr. Andreas Herrmann today proudly reports the conclusion of the production campaign providing the first larger batch of COR-101 ready for the patients. COR-101 is a fully human antibody developed in Braunschweig which...
